William Blair Comments on Billiontoone Q3 Earnings

Billiontoone, Inc. (NASDAQ:BLLN) – William Blair issued their Q3 2025 earnings per share (EPS) estimates for shares of Billiontoone in a research note issued to investors on Monday, December 1st. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of $0.14 for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Billiontoone’s Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.04) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.51 EPS and FY2028 earnings at $1.42 EPS.

A number of other brokerages have also recently issued reports on BLLN. Jefferies Financial Group started coverage on shares of Billiontoone in a research note on Monday. They issued a “hold” rating and a $117.00 price objective for the company. BTIG Research initiated coverage on shares of Billiontoone in a research note on Monday. They issued a “buy” rating and a $160.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of Billiontoone in a research note on Monday. They set a “buy” rating and a $145.00 price target for the company. Wall Street Zen raised Billiontoone to a “hold” rating in a report on Saturday, November 15th. Finally, Piper Sandler started coverage on Billiontoone in a report on Monday. They issued an “overweight” rating and a $150.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $138.67.

Billiontoone Price Performance

Shares of NASDAQ BLLN opened at $102.76 on Wednesday. Billiontoone has a one year low of $88.00 and a one year high of $138.70.

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.